Prostate cancer

Advances in immunotherapy

Arthur A. Hurwitz, Paul Yanover, Mary Markowitz, James P. Allison, Eugene D Kwon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to the treatment of prostate cancer. Immune-based strategies for treating prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumour antigens that can be targeted, either by antibody or T cells, to promote prostate tumour cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumours. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of T cell costimulatory pathway receptors can greatly facilitate tumour-specific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. For example, blocking T cell cytotoxic lymphocyte-associated antigen 4 (CTLA-4) receptor binding to its ligand prevents the down-regulation of T cell responses and can even potentiate T cell antitumoural immunity in mouse models of prostate cancer. Androgen ablation (AA) may induce prostate tumour/tissue-specific T cell mediated inflammation and, as such, a phase II trial is currently in progress to ascertain whether CTLA-4 blockade can enhance AA-induced treatment responses in patients with advanced prostate cancer. Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalBioDrugs
Volume17
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Immunotherapy
Prostatic Neoplasms
Prostate
T-Lymphocytes
Neoplasms
Antigens
Androgens
Costimulatory and Inhibitory T-Cell Receptors
CD27 Antigens
Lymphocytes
Therapeutics
Antigen Receptors
Neoplasm Antigens
Cellular Immunity
Dendritic Cells
Immunity
Down-Regulation
Vaccines
Ligands
Inflammation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hurwitz, A. A., Yanover, P., Markowitz, M., Allison, J. P., & Kwon, E. D. (2003). Prostate cancer: Advances in immunotherapy. BioDrugs, 17(2), 131-138. https://doi.org/10.2165/00063030-200317020-00005

Prostate cancer : Advances in immunotherapy. / Hurwitz, Arthur A.; Yanover, Paul; Markowitz, Mary; Allison, James P.; Kwon, Eugene D.

In: BioDrugs, Vol. 17, No. 2, 2003, p. 131-138.

Research output: Contribution to journalArticle

Hurwitz, AA, Yanover, P, Markowitz, M, Allison, JP & Kwon, ED 2003, 'Prostate cancer: Advances in immunotherapy', BioDrugs, vol. 17, no. 2, pp. 131-138. https://doi.org/10.2165/00063030-200317020-00005
Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: Advances in immunotherapy. BioDrugs. 2003;17(2):131-138. https://doi.org/10.2165/00063030-200317020-00005
Hurwitz, Arthur A. ; Yanover, Paul ; Markowitz, Mary ; Allison, James P. ; Kwon, Eugene D. / Prostate cancer : Advances in immunotherapy. In: BioDrugs. 2003 ; Vol. 17, No. 2. pp. 131-138.
@article{e67cbcd15a724a758ed7831f00b5a1e4,
title = "Prostate cancer: Advances in immunotherapy",
abstract = "The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to the treatment of prostate cancer. Immune-based strategies for treating prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumour antigens that can be targeted, either by antibody or T cells, to promote prostate tumour cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumours. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of T cell costimulatory pathway receptors can greatly facilitate tumour-specific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. For example, blocking T cell cytotoxic lymphocyte-associated antigen 4 (CTLA-4) receptor binding to its ligand prevents the down-regulation of T cell responses and can even potentiate T cell antitumoural immunity in mouse models of prostate cancer. Androgen ablation (AA) may induce prostate tumour/tissue-specific T cell mediated inflammation and, as such, a phase II trial is currently in progress to ascertain whether CTLA-4 blockade can enhance AA-induced treatment responses in patients with advanced prostate cancer. Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option.",
author = "Hurwitz, {Arthur A.} and Paul Yanover and Mary Markowitz and Allison, {James P.} and Kwon, {Eugene D}",
year = "2003",
doi = "10.2165/00063030-200317020-00005",
language = "English (US)",
volume = "17",
pages = "131--138",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Prostate cancer

T2 - Advances in immunotherapy

AU - Hurwitz, Arthur A.

AU - Yanover, Paul

AU - Markowitz, Mary

AU - Allison, James P.

AU - Kwon, Eugene D

PY - 2003

Y1 - 2003

N2 - The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to the treatment of prostate cancer. Immune-based strategies for treating prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumour antigens that can be targeted, either by antibody or T cells, to promote prostate tumour cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumours. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of T cell costimulatory pathway receptors can greatly facilitate tumour-specific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. For example, blocking T cell cytotoxic lymphocyte-associated antigen 4 (CTLA-4) receptor binding to its ligand prevents the down-regulation of T cell responses and can even potentiate T cell antitumoural immunity in mouse models of prostate cancer. Androgen ablation (AA) may induce prostate tumour/tissue-specific T cell mediated inflammation and, as such, a phase II trial is currently in progress to ascertain whether CTLA-4 blockade can enhance AA-induced treatment responses in patients with advanced prostate cancer. Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option.

AB - The absence of curative therapies for advanced or recurrent forms of prostate cancer has prompted a vigorous search for novel treatment strategies. Immunotherapy encompasses one particularly promising systemic approach to the treatment of prostate cancer. Immune-based strategies for treating prostate cancer have recently been facilitated by the identification of a number of prostate tissue/tumour antigens that can be targeted, either by antibody or T cells, to promote prostate tumour cell injury or death. These same prostate antigens can also be used for the construction of vaccines to induce prostate-specific T cell-mediated immunity. Greater insight into specific mechanisms that govern antigen-specific T cell activation has brought with it a number of innovative methods to induce and enhance T cell-mediated responses against prostate tumours. For instance, autologous dendritic cells loaded with prostate antigens have proved useful to induce prostate-specific T cell activation. Similarly, in vivo manipulations of T cell costimulatory pathway receptors can greatly facilitate tumour-specific T cell activation and potentiate T cell-mediated responses against a number of malignancies, including prostate cancer. For example, blocking T cell cytotoxic lymphocyte-associated antigen 4 (CTLA-4) receptor binding to its ligand prevents the down-regulation of T cell responses and can even potentiate T cell antitumoural immunity in mouse models of prostate cancer. Androgen ablation (AA) may induce prostate tumour/tissue-specific T cell mediated inflammation and, as such, a phase II trial is currently in progress to ascertain whether CTLA-4 blockade can enhance AA-induced treatment responses in patients with advanced prostate cancer. Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option.

UR - http://www.scopus.com/inward/record.url?scp=0037261716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037261716&partnerID=8YFLogxK

U2 - 10.2165/00063030-200317020-00005

DO - 10.2165/00063030-200317020-00005

M3 - Article

VL - 17

SP - 131

EP - 138

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 2

ER -